首页> 中国专利> 试剂在制备药物中的用途、干涉片段、抑制肝癌肿瘤干细胞自我更新方法和治疗肝癌药物

试剂在制备药物中的用途、干涉片段、抑制肝癌肿瘤干细胞自我更新方法和治疗肝癌药物

页面导航

摘要
著录项
相似文献

摘要

本发明提出了试剂在制备药物中的用途，所述药物用于治疗肝癌，所述试剂用于抑制MCM7蛋白的表达。MCM7蛋白参与肝癌肿瘤干细胞自我更新的调控，通过抑制MCM7蛋白的表达，可以抑制肝癌肿瘤干细胞的自我更新，起到治疗肝癌的目的。

著录项

公开/公告号CN109288855B

专利类型发明专利
公开/公告日2021-08-17

原文格式PDF
申请/专利权人中国人民解放军军事科学院军事医学研究院;
展开▼

申请/专利号CN201811108700.7
发明设计人周军年;裴雪涛;岳文;王海洋;张彪;王东星;曾泉;
展开▼

申请日2018-09-21
分类号A61K31/713(20060101);A61K48/00(20060101);A61P35/00(20060101);C12N15/113(20100101);C12N15/867(20060101);
代理机构11201 北京清亦华知识产权代理事务所(普通合伙);
代理人赵天月
地址 100850 北京市海淀区太平路27号
入库时间 2022-08-23 12:19:39

相似文献

专利
中文文献
外文文献

1. 试剂在制备药物中的用途、干涉片段、抑制肝癌肿瘤干细胞自我更新方法和治疗肝癌药物 [P] . 中国专利： CN109288855B . 2021.08.17
2. 试剂在制备药物中的用途、干涉片段、抑制肝癌肿瘤干细胞自我更新方法和治疗肝癌药物 [P] . 中国专利： CN109288855A . 2019-02-01
3. methods for screening for a therapeutic agent, for suppressing the polynucleotide sequence, for treating a non-steroidal cancer, for screening for binding of an agent specifically to a polynucleotide, and for determining whether a patient is at risk for developing or having a non-steroidal cancer, pharmaceutical composition, uses of a therapeutic agent, an antisense molecule or a cell that expresses and / or contains the antisense molecule, at least one of the immunogenic membrane proteins, fragments, derivatives or homologues thereof or from a cell containing and / or expressing at least one of the immunogenic membrane proteins or fragments, derivatives or homologues thereof and an agent or antibody, agent, and kit for identifying a patient at risk of developing or have non-steroidal cancer [P] . BRPI0414446A . 2006-11-14

机译：筛选治疗剂，抑制多核苷酸序列，治疗非甾体类癌症，筛选试剂特异性结合多核苷酸的方法以及确定患者是否处于发展或患有非糖尿病风险的方法类固醇癌，药物组合物，表达和/或含有反义分子的治疗剂，反义分子或细胞，免疫原性膜蛋白，其片段，衍生物或同源物中至少一种或来自含有和/或含有细胞的细胞的用途或表达至少一种免疫原性膜蛋白或其片段，衍生物或同系物以及一种试剂或抗体，试剂和试剂盒，用于鉴定有发生或患有非甾体癌风险的患者
4. Toluensulfonico acid salt of P - amino - 5 - 3 - (2 '- O - acetyl - 3' - Deoxy - beta-d - ribofuranosil 3H) - thiazole 4, 5 - d pyrimidine 2 - ona, Methods for preparing the same and their Synthesis Intermediates, a that includes Pharmaceutical Composition and its use in the Treatment of Viral Infections and ca [P] . AR063484A1 . 2009-01-28

机译： P-氨基-5-3-（2'-O-乙酰-3'-脱氧-β-d-呋喃核糖3H）-噻唑[4，5-d]嘧啶2-ona的甲苯磺酸盐，制备方法药物及其合成中间体，包括药物组合物及其在治疗病毒感染和肝癌中的用途
5. composition, pharmaceutical composition, effervescent dosage form, multiple unit oral oral pharmaceutical composition, extended release pharmaceutical dosage form, enteric coated pharmaceutical dosage form, stable pharmaceutical dosage form for oral administration to mammalian subjects, method for treating diseases acid-related diseases by inhibiting gastric acid secretion, method for treating a bacterial infection caused or caused by helicobacter pylori, process for preparing a compound of formula 3, process for preparing a compound of formula 5, use of a compound of formula 1 for the preparation of a medicament for treating gastric acid-related diseases by inhibiting gastric acid secretion, use of a compound of formula 1 for the preparation of a medicament for treating a bacterial infection caused or caused by helicobacter pyl or use of a compound of formula 1 for the preparation of a medicament for treating gastric acid-related diseases by inhibiting gastric acid secretion [P] . BRPI0617987A2 . 2011-08-16

机译：组合物，药物组合物，泡腾剂型，多单位口服口服药物组合物，缓释药物剂型，肠溶衣药物剂型，向哺乳动物受试者口服给药的稳定药物剂型，通过抑制胃酸治疗疾病的方法酸分泌，治疗由幽门螺杆菌引起或引起的细菌感染的方法，制备式3化合物的方法，制备式5化合物的方法，式1化合物在制备用于治疗胃的药物中的用途通过抑制胃酸分泌来治疗与酸有关的疾病，将式1的化合物用于制备用于治疗由幽门螺杆菌引起或引起的细菌感染的药物，或将式1的化合物用于制备用于治疗的药物通过抑制胃酸分泌来治疗胃酸相关疾病